108 active
/
431 total (since 2015)
23
Phase 1 Active
130 total
39
Phase 2 Active
138 total
33
Phase 3 Active
117 total
22
Phase 4 Active
79 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Neurocrine Biosciences 6 7 3
Luye Pharma Group Ltd. 6 5 0
Bristol-Myers Squibb 4 0 0
Otsuka Pharmaceutical Co., Ltd. 3 2 1
Otsuka Pharmaceutical Development & Commercialization, Inc. 2 25 5
Alkermes, Inc. 2 10 0
BioXcel Therapeutics Inc 2 4 0
LB Pharmaceuticals Inc. 2 3 0
Vanda Pharmaceuticals 2 3 0
MapLight Therapeutics 2 0 0
Vigonvita Life Sciences 2 0 0
Qilu Pharmaceutical Co., Ltd. 2 0 0
Karuna Therapeutics 1 9 1
AbbVie 1 4 2
Intra-Cellular Therapies, Inc. 1 5 0
NCT05304767 RECRUITING
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Karuna Therapeutics n=280
NCT06963034 RECRUITING
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences n=284
NCT07084831 RECRUITING
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
European Group for Research In Schizophrenia n=171
NCT07288567 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb n=166
NCT07424404 RECRUITING
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=400
NCT06882785 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Bristol-Myers Squibb n=250
NCT04987229 ENROLLING BY INVITATION
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
Alkermes, Inc. n=236
NCT06894212 RECRUITING
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=522
NCT05303064 RECRUITING
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc. n=220
NCT07263022 NOT YET RECRUITING
Cognitive Strategies in Early Psychosis 2
University of Minnesota n=24
NCT07184619 RECRUITING
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Newron Pharmaceuticals SPA n=400
NCT07369154 NOT YET RECRUITING
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc. n=900
NCT07363577 NOT YET RECRUITING
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc. n=456
NCT05603104 RECRUITING
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Dr. Inge Winter n=1,254
NCT07225712 RECRUITING
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=100
NCT06961968 RECRUITING
Randomized Withdrawal Study in Patients With Schizophrenia
Vanda Pharmaceuticals n=400
NCT05838573 RECRUITING
Metformin Treatment on Cognitive Impairment of Schizophrenia
Central South University n=120
NCT07045142 RECRUITING
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
Central South University n=400
NCT07227818 NOT YET RECRUITING
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences n=560
NCT07114874 RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences n=800
NCT03817502 RECRUITING
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Gedeon Richter Plc. n=330
NCT06191965 RECRUITING
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Mclean Hospital n=100
NCT07105098 RECRUITING
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences n=284
NCT06229210 RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc. n=500
NCT05325645 RECRUITING
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=450
NCT06799559 NOT YET RECRUITING
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
Qilu Pharmaceutical Co., Ltd. n=402
NCT05184335 RECRUITING
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Reviva Pharmaceuticals n=690
NCT05326347 ACTIVE NOT RECRUITING
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=190
NCT06649214 NOT YET RECRUITING
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
Qilu Pharmaceutical Co., Ltd. n=654
NCT06589817 NOT YET RECRUITING
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
Chengdu Kanghong Pharmaceutical Group Co., Ltd. n=376
NCT06482554 RECRUITING
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Louisiana State University Health Sciences Center Shreveport n=80
NCT06351514 RECRUITING
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Institute of Mental Health, Singapore n=40
NCT03094429 RECRUITING
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
SyneuRx International (Taiwan) Corp n=287
NCT05110157 COMPLETED
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Neurocrine Biosciences n=442
NCT04857983 COMPLETED
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
University of California, San Diego n=62
NCT04860830 COMPLETED
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
Boehringer Ingelheim n=609
NCT03238326 COMPLETED
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=295
NCT05693935 COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
Teva Branded Pharmaceutical Products R&D LLC n=675
NCT04115319 COMPLETED
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
Otsuka Pharmaceutical Development & Commercialization, Inc. n=305
NCT05919823 COMPLETED
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
Karuna Therapeutics n=202
NCT04846881 COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
Boehringer Ingelheim n=611
NCT05741528 COMPLETED
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Otsuka Pharmaceutical Development & Commercialization, Inc. n=75
NCT05628103 COMPLETED
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
Otsuka Pharmaceutical Development & Commercialization, Inc. n=101
NCT03485417 COMPLETED
Substance Misuse To Psychosis for Stimulants
The University of Hong Kong n=165
NCT04846868 COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
Boehringer Ingelheim n=620
NCT04578756 COMPLETED
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
AbbVie n=310
NCT05368558 TERMINATED
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
AbbVie n=34
NCT06067984 COMPLETED
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
Click Therapeutics, Inc. n=73
NCT05838625 COMPLETED
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
Click Therapeutics, Inc. n=464
NCT02469155 COMPLETED
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Intra-Cellular Therapies, Inc. n=696
NCT05658510 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
BioXcel Therapeutics Inc n=452
NCT04820309 COMPLETED
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
Karuna Therapeutics n=566
NCT03121586 TERMINATED
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
ACADIA Pharmaceuticals Inc. n=995
NCT04531982 COMPLETED
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
ACADIA Pharmaceuticals Inc. n=454
NCT05211947 TERMINATED
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
Boehringer Ingelheim n=1,362
NCT03345342 COMPLETED
A Study of Paliperidone Palmitate 6-Month Formulation
Janssen Research & Development, LLC n=841
NCT04072575 COMPLETED
A Study of Paliperidone Palmitate 6-Month Formulation
Janssen Research & Development, LLC n=178
NCT02431702 COMPLETED
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
Janssen Scientific Affairs, LLC n=337
NCT02713282 COMPLETED
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Janssen-Cilag Ltd. n=306
NCT03874494 COMPLETED
Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia
Otsuka Beijing Research Institute n=371
NCT06878833 WITHDRAWN
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
Lyndra Inc.
NCT03510325 COMPLETED
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
Shanghai Mental Health Center n=762
NCT06572449 COMPLETED
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
Karuna Therapeutics n=173
NCT05145413 COMPLETED
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Karuna Therapeutics n=396
NCT05359081 TERMINATED
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
Sumitomo Pharma Co., Ltd. n=68
NCT04109950 TERMINATED
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=463
NCT04738123 COMPLETED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Karuna Therapeutics n=256
NCT05654870 TERMINATED
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
Neurocrine Biosciences n=8
NCT04959032 COMPLETED
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Intra-Cellular Therapies, Inc. n=228
NCT04659174 COMPLETED
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
Karuna Therapeutics n=152
NCT05779241 COMPLETED
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Lyndra Inc. n=83
NCT03437668 TERMINATED
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
Chengappa, K.N. Roy, MD n=47
NCT03201757 COMPLETED
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Alkermes, Inc. n=523
NCT02685748 COMPLETED
Aspirin in Young Psychotic Patients
Clinic for Psychiatric Disorders, Dr Laza Lazarevic n=60
NCT04072354 COMPLETED
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=463
NCT04092686 COMPLETED
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=464
NCT05643170 TERMINATED
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Karuna Therapeutics n=4
NCT03896945 TERMINATED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=136
NCT02261519 TERMINATED
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
SyneuRx International (Taiwan) Corp n=280
NCT04825860 TERMINATED
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
Sumitomo Pharma Co., Ltd. n=83
NCT03198078 COMPLETED
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=316
NCT04659161 COMPLETED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
Karuna Therapeutics n=252
NCT04268303 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
BioXcel Therapeutics Inc n=380
NCT03397134 COMPLETED
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
Minerva Neurosciences n=515
NCT03503318 COMPLETED
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
Teva Branded Pharmaceutical Products R&D, Inc. n=544
NCT03465787 COMPLETED
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
Bukwang Pharmaceutical n=210
NCT03187769 COMPLETED
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
Alkermes, Inc. n=426
NCT03893825 COMPLETED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
Teva Branded Pharmaceutical Products R&D, Inc. n=336
NCT03788759 COMPLETED
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara n=48
NCT03149107 TERMINATED
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
University Hospital, Bonn n=48
NCT03593213 TERMINATED
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia
AbbVie n=587
NCT03870880 COMPLETED
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
Rovi Pharmaceuticals Laboratories n=215
NCT03160521 COMPLETED
Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
Rovi Pharmaceuticals Laboratories n=438
NCT04327843 COMPLETED
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
Case Western Reserve University n=22
NCT03043820 COMPLETED
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
Iris Sommer n=110
NCT03892889 TERMINATED
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Otsuka Pharmaceutical Development & Commercialization, Inc. n=277
NCT03955549 COMPLETED
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
Agiad Psychiatry Hospital n=99
NCT02873208 COMPLETED
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Alkermes, Inc. n=266
NCT02983188 COMPLETED
Berberine as Adjuvant Treatment for Schizophrenia Patients
The University of Hong Kong n=113
NCT03172871 COMPLETED
Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
Otsuka Beijing Research Institute n=436
NCT02892422 COMPLETED
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
H. Lundbeck A/S n=528
NCT02876900 COMPLETED
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
Noven Pharmaceuticals, Inc. n=617
NCT03345979 COMPLETED
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Alkermes, Inc. n=200
NCT02970292 COMPLETED
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
ACADIA Pharmaceuticals Inc. n=396
NCT03848234 COMPLETED
Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder
Tangent Data n=209
NCT02773576 COMPLETED
Safety and Tolerability of Risperidone Implants
Braeburn Pharmaceuticals n=140
NCT02694328 COMPLETED
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
Alkermes, Inc. n=561
NCT03230864 TERMINATED
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
H. Lundbeck A/S n=119
NCT02717195 COMPLETED
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
H. Lundbeck A/S n=1,098
NCT02669758 COMPLETED
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Alkermes, Inc. n=281
NCT03915938 COMPLETED
Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain
Hospital de Clinicas de Porto Alegre n=24
NCT02194933 COMPLETED
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
Otsuka Pharmaceutical Development & Commercialization, Inc. n=38
NCT02634346 COMPLETED
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Alkermes, Inc. n=403
NCT02374567 TERMINATED
Pharmacovigilance in Gerontopsychiatric Patients
Hannover Medical School n=407
NCT02308956 COMPLETED
Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
University of Cape Town n=324
NCT02758067 WITHDRAWN
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
H. Lundbeck A/S
Data: ClinicalTrials.gov